Wa T C, Burns N J, Williams B C, Freestone S, Lee M R
Department of Medicine, Royal Infirmary, Edinburgh.
Br J Clin Pharmacol. 1995 Mar;39(3):327-9. doi: 10.1111/j.1365-2125.1995.tb04456.x.
Six healthy male subjects received equimolar amounts of two 5-hydroxytryptamine (5-HT) precursors, 5-hydroxy-L-tryptophan (5-HTP) and gamma-L-glutamyl-5-hydroxy-L-tryptophan (glu-5-HTP), on two occasions in a randomised cross-over study. There were marked increases in urinary 5-HTP and 5-HT excretion after infusion of both compounds. Mean urinary excretion rate of 5-HT, which was < 0.7 nmol min-1 before dosing, rose to a peak value of 412 +/- 92 nmol min-1 at the end of 5-HTP infusion and 303 +/- 29 nmol min-1 after administration of glu-5-HTP. This occurred without significant changes in blood 5-HT levels measured in platelet-rich plasma. These findings provide further evidence that the increase in urine 5-HT after administration of both 5-HT precursors is largely due to 5-HT synthesised within the kidney.
在一项随机交叉研究中，六名健康男性受试者分两次接受了等摩尔量的两种5-羟色胺（5-HT）前体，即5-羟-L-色氨酸（5-HTP）和γ-L-谷氨酰-5-羟-L-色氨酸（glu-5-HTP）。输注这两种化合物后，尿中5-HTP和5-HT排泄量显著增加。给药前5-HT的平均尿排泄率<0.7 nmol min⁻¹，在5-HTP输注结束时升至峰值412±92 nmol min⁻¹，给予glu-5-HTP后为303±29 nmol min⁻¹。在富含血小板的血浆中测量的血液5-HT水平没有显著变化的情况下，这种情况仍会发生。这些发现进一步证明，两种5-HT前体给药后尿中5-HT的增加主要是由于肾脏内合成的5-HT。
